Compare Church & Dwight Co., Inc. (CHD) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Church & Dwight Co., Inc. vs Novavax Inc — how do they compare? Church & Dwight Co., Inc. trades at $101.84 (market cap $24.38B), while Novavax Inc trades at $7.93 (market cap $1.31B). The key difference: Church & Dwight Co., Inc. is far larger — about 18.6× Novavax Inc's market cap, and Church & Dwight Co., Inc. pays a 1.2% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| CHD | NVAX | |
|---|---|---|
Market Cap | $24.38B | $1.31B |
Sector | Consumer Staples | Health |
52-Week High | $105.26 | $11.19 |
52-Week Low | $81.60 | $6.22 |
Enterprise Value | $26.38B | $889.30M |
Dividend Yield | 1.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Church & Dwight (CHD) trades at $101.99, down 1.27% today, with a bullish technical signal and strong fundamentals. Recent Q2 2026 earnings met estimates with 5.8% organic sales growth, and the company raised full-year guidance. Valuation ratios like P/E of 32.94 are elevated, but profitability remains solid with an 11.96% net income margin.
The outlook is positive due to consistent earnings beats and raised guidance, though high valuation and competitive pressures pose risks. Analyst consensus is bullish with a $103.57 price target, supported by institutional holdings and dividend stability.
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Church & Dwight Co., Inc.
Church & Dwight is the leading producer of baking soda in the world. Beyond baking soda, the products in its portfolio have vast category reach, including laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its mix also includes Xtra, Trojan, OxiClean, First Response, Nair, L'il Critters/Vitafusion, Orajel, and WaterPik, which together with Arm & Hammer constitute more than 80% of its annual sales and profits. In early 2019, the firm announced the addition of Flawless, which manufactures electric shaving products for women. At the end of 2020, the firm acquired Zicam, a leading brand in the cough/cold-shortening category. Church & Dwight derives more than 80% of its sales from its home market in the U.S.
Read more on CHD →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
